鼻副鼻腔疾患に伴う頭痛,顔面痛

Size: px
Start display at page:

Download "鼻副鼻腔疾患に伴う頭痛,顔面痛"

Transcription

1 : VV CT : Sluder CT CT VV V V V

2 V V V V Sluder neuralgia Sluder Sluder Sluder neuralgia V C2 4 CT MRI CT CT CT OM V V V V

3 a b c d e f g h 1 CT : : : : : :

4 a b 2 CT MRI a b 3 CT : : : CT MRI : : CT MRI MRI : : CT :

5 a b c 4 CT: CT : MRI : CT : : : CT CT MRI : : CT MRI : : : MRI : AFRS : : CT :

6 a b 5 MRI : MRI : a b 6 CT : CT : IgE AFRS CT window level : CT AFRS CT : : CT CT

7 CT : CT : : A11 5 CT CT CT CT MRI Platzer W :.. Platzer E,, ; :. Ahamed SH, Sci MB, Jones NS : What is Sluder s neuralgia? J Laryngol Otol 2003 ; 117 : Sluder G : The role of the sphenopalatine or meckel s ganglion in nasal headaches. NY Med J 1908 ; 87 : , : Sinus pain ; 26 : : normal variant.. ; :. :.. ; :.,,, :. ; :. :. ; :.,

8 : A11.,,,,,,,.. ; :.

untitled

untitled 186 17 100160250 1 10.1 55 2 18.5 6.9 100 38 17 3.2 17 8.4 45 3.9 53 1.6 22 7.3 100 2.3 31 3.4 47 OR OR 3 1.20.76 63.4 2.16 4 38,937101,118 17 17 17 5 1,765 1,424 854 794 108 839 628 173 389 339 57 6 18613

More information

untitled

untitled 1. 3 14 2. 1 12 9 7.1 3. 5 10 17 8 5500 4. 6 11 5. 1 12 101977 1 21 45.31982.9.4 79.71996 / 1997 89.21983 41.01902 6. 7 5 10 2004 30 16.8 37.5 3.3 2004 10.0 7.5 37.0 2004 8. 2 7 9. 6 11 46 37 25 55 10.

More information

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26

104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

untitled

untitled 1907(40) 100 100 21 1 1 21 21 21 21 21 1891(M24) 1920(T9)1 2 1932(S7) 1947(S22) 1968(S43)12 2001(H13) 1955(S30) 1 24 9 7 22 43 13 2 100 6 200300t 1896M29 3876 1536 1 15 1907(M7) 11 6 1898(M31) 5 6 2 1912(M45)

More information

-2-

-2- Super Lizer HT-2200 m m W Super Lizer -1- -2- -3- -4- stellate ganglion block stellate ganglion -5- -6- -7- -8- IgA -9- " " -10- -11- 5 6 10 1-12- -1- -2- mv -3- -4- -5- -1- : -2- No.2576 P.25 1973-3-

More information

- 2 -

- 2 - - 1 - - 2 - - 3 - - 4 - - 5 - ( ) - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - What is your hobby? - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27

More information

,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,

,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1, 1 1 1 2 1 3 1 4 2 5 5 6 6 1 6 2 7 3 7 4 7 5 7 7 8 8 10 1 10 2 10 3 10 12 1 12 2 12 3 12 4 13 5 14 14 1 14 1 2 3 4 5 1 2 3 4 16 5 16 6 16 7 17 6 17 18 19~23-19- 1 0.5 1 43.25 2.20 3.60 103.50 43.88 2.20

More information

16 10 19

16 10 19 16 10 19 1 1 10 10 11 10 12 10 2 13 10 14 10 15 16 15 17 15 18 15 19 15 20 21 20 22 20 23 20 24 20 3 26 28 29 30 31 32 33 34 35 36 38 39 40 41 42 4 10 10 11 10 12 10 13 10 5 14 10 15 16 15 17 15 18 15

More information

肝臓病教室201207v2配布用.pptx

肝臓病教室201207v2配布用.pptx 24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

More information

8 8 0

8 8 0 ,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

More information

1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%

More information

報告書

報告書 1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015

More information

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9

; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9 32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5

More information

5 30 4 5 3 1

5 30 4 5 3 1 Dr.. No..10??!!!!!! ((^^ Dr.. 5 30 4 5 3 1 cool 1 1 2 200 1700 5 TQM TQM TQM TQM TQM QC 3 or TQM QC QC TQM H24 TQM OK 598 TQM ょ っ ~ っ ~ 12 2012 Y 4 NY ,, http://www.yonemorihp.jp 2 2950 2 2710

More information

Microsoft Word - Œ{Ł¶.doc

Microsoft Word - Œ{Ł¶.doc 17 59.0% 41.0% 60.8% 76.0%71.9% 65.3% 17 2.6% 3.5% 25.9% 57.3% 16.7% 28.1% 52.2% 11.1% 2.6% =270 18 2 (=199) 1 17 71.0% 76.0% 44.2% 71.9% 36.2% 18.1% 65.3% 16.7% 34.1% 16.3% 47.1% 14.9% 13.8% 5.0% 3.6%

More information

好酸球性副鼻腔炎:診断ガイドライン(JESREC Study)

好酸球性副鼻腔炎:診断ガイドライン(JESREC Study) 118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc

More information

A 01 2 015 10 11 12 G 011 2 0111 67

A 01 2 015 10 11 12 G 011 2 0111 67 66 A 01 2 015 10 11 12 G 011 2 0111 67 0119 0112 0113 68 0130 0128 0114 0113 0115 0116 0119 69 0111 0128 012 2 0121 1102 0122 0123 0124 70 0125 0126 0126 0111 0127 71 0128 0129 0230 013 0130 0130 011 012

More information

untitled

untitled 1 2 1 3 1 3 2 5 2 9 12 1 12 2 14 3 16 4 17 5 19 6 22 23 1 23 1 23 2 23 3 24 4 25 5 26 6 27 2 27 31 35 40 41 1 41 2 43 3 46 2 48 3 55 1 62 2 63 3 64 4 81 23 4 1 2 3 4 2 3 17-1 - 6 1) 2) 1 1-2 - - 3 - 3

More information

0.02ml IgE RAST MAST CAP 2

0.02ml IgE RAST MAST CAP 2 ( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 20 20 2003 15 1990 1990 2002 2002 12 12.....?. or 32 TN M0 1999 10 T1N0M0 93 10 dental CT dental CT MRI MRI : 55 TN0M0 1993 12 57 T3N0M0 938 1990 T1N0M0 1989 12 1990 99 99 4 T4 T4 T4 v.s.t2,3 T4 v.s.t2,3?

More information

kaiho42.pdf

kaiho42.pdf 第 42号 平成25年1月14日 http://www.matsue-taikyo.com/ om/ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54

More information

JPN-1

JPN-1 EF70-200mm f/2.8l IS II USM JPN JPN-1 a JPN-2 JPN-3 1. JPN-4 2. 3. JPN-5 4. JPN-6 5. JPN-7 6. JPN-8 7. JPN-9 JPN-10 8. 9. JPN-11 10. JPN-12 11. 12. 13. JPN-13 14. JPN-14 JPN-15 canon.jp/ef 050-555-90001

More information

Digital Photo Professional Ver1.6(Windows)

Digital Photo Professional Ver1.6(Windows) Windows CT1-5193-000 CANON INC. 2005 J 1 2 3 4 s s s 1 1 s s s s s 1 1 a s s 1 s s 1 2 s a 1 s a 2 3 1 1 s a a 2 a 3 a s s 1 a a s a s s 1 s s 1 2 3 s 1 1 a 2 a 1 a s 2 3 1 1 s a 2 1 3 1 s a 2

More information

アナウンスマニュアル

アナウンスマニュアル (1). (2). a. b. c. a. c. c. (3). 1 ( ) ( ) 2 (1). (2). (3). 3 () """" 4 ( ) ( ) ( ) ( ) 5 ( ) 6 () () () () () () () () () () () () () () () () () () () 7 () () () () () () () () () () () () () () () ()

More information

橡ボーダーライン.PDF

橡ボーダーライン.PDF 1 ( ) ( ) 2 3 4 ( ) 5 6 7 8 9 10 11 12 13 14 ( ) 15 16 17 18 19 20 ( ) 21 22 23 24 ( ) 25 26 27 28 29 30 ( ) 31 To be or not to be 32 33 34 35 36 37 38 ( ) 39 40 41 42 43 44 45 46 47 48 ( ) 49 50 51 52

More information

untitled

untitled 1. 1 2. 2 3.,1995 3 223119 3.1,, 4 3.2 NTT,2003 5 mile,2003 4.,, 6 , 2001 22 126 7 9 34 22 22 8 (139) 8 6. 6.1,,,,,, 9 6.2a Who What Whom When How Where 3 4 5 4 8 8 4, 7 6,,,, 2 or 3 6.2NGO NGO Who What

More information

Microsoft Word - .....J.^...O.|Word.i10...j.doc

Microsoft Word - .....J.^...O.|Word.i10...j.doc P 1. 2. R H C H, etc. R' n R' R C R'' R R H R R' R C C R R C R' R C R' R C C R 1-1 1-2 3. 1-3 1-4 4. 5. 1-5 5. 1-6 6. 10 1-7 7. 1-8 8. 2-1 2-2 2-3 9. 2-4 2-5 2-6 2-7 10. 2-8 10. 2-9 10. 2-10 10. 11. C

More information

がん診療におけるFDG FDG-PET/CTの役割

がん診療におけるFDG FDG-PET/CTの役割 PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT

More information

210-0004 TEL 200-3298,3300 FAX 222-1442 14 ( ) 14 ( ) 7 ( ) 16 ( ) 16 ( ) 23 ( ) (%) 1 ( ) 1 ( ) 2 ( ) 7 ( ) 7 ( ) 22 ( ) 8 ( ) 22 ( ) 30 ( ) or 31( )

210-0004 TEL 200-3298,3300 FAX 222-1442 14 ( ) 14 ( ) 7 ( ) 16 ( ) 16 ( ) 23 ( ) (%) 1 ( ) 1 ( ) 2 ( ) 7 ( ) 7 ( ) 22 ( ) 8 ( ) 22 ( ) 30 ( ) or 31( ) 210-0004 TEL 200-3298,3300 FAX 222-1442 10:00 14:00 210-0004 TEL 200-3298,3300 FAX 222-1442 14 ( ) 14 ( ) 7 ( ) 16 ( ) 16 ( ) 23 ( ) (%) 1 ( ) 1 ( ) 2 ( ) 7 ( ) 7 ( ) 22 ( ) 8 ( ) 22 ( ) 30 ( ) or 31(

More information

被曝二世健康影響調査

被曝二世健康影響調査 19 3 1 1. 3 2. 4 4 4 6 7 8 8 3. 10 10 10 11 12 4. 14 14 15 15 15 15 16 17 17 18 18 19 19 5. 20 6. 21 22 2000 7 5 4 6 4 77,000 5mGy 5mGy 24,673 57.3 84.5% 11,951 BMI 1 - 1Gy 0.91 1Gy 0.98-48.6 48.4 19 10

More information

1 1 1 46111 2 1061.0 106.3 1/10 24721 90 25 1/4 243 3 23 25 1.4 512 120 280 260 100 240 220 80 200 180 160 60 140 120 40 100 80 20 60 40 20 0 0 55 56 57 58 59 60 61 62 63 2 3 4 5 6 7 8 9 10 11 12 13 14

More information

4

4 4 r r 43 44 a b c f d e a r b c d e f 45 r r r 46 47 a b g a b r c d e f r g c d e f e 48 mm r r 1 49 a r b c a b 1 1 a 3 a 50 1 a 3 1 mb a 1 mm 3 a a a 51 1 mm 1 mm 1 5 mb 3 4 1 3 4 1 53 1 1 mj r 1 a

More information

21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony

More information

03 04 5 1 93 1 35 1 3 5 10 12 2001 06 03 10 01 04 04 22 7 1 04 70280 50280 : 70-280 50-280 100 1005,000 3,500 800 or :800 2035 1035 48,510 36,380 70 300 :25 400 :30 700 :35 700 :40 (2,000 35 44 ) 3,150

More information

2

2 1 2 3 1) 2) 3) 2 3 1 2 3 4 5 6 7 8 9 10 11 4 12 13 14 15 X 16 X 17 X CT 18 MRI 19 20 4 A. ENG T&T B. ABLB SISI ABR ASSRMLRSRL 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 6 1 2 3 4 7 1 POS( Problem

More information

橡Taro9-生徒の活動.PDF

橡Taro9-生徒の活動.PDF 3 1 4 1 20 30 2 2 3-1- 1 2-2- -3- 18 1200 1 4-4- -5- 15 5 25 5-6- 1 4 2 1 10 20 2 3-7- 1 2 3 150 431 338-8- 2 3 100 4 5 6 7 1-9- 1291-10 - -11 - 10 1 35 2 3 1866 68 4 1871 1873 5 6-12 - 1 2 3 4 1 4-13

More information

untitled

untitled 59 2014 712 59 2014 712 59 171 3F 2F 1F B2F B3F B2F 900 1 2 3 900930 900 1630 30940 1000 1100 9401140 9401050 1 D11 D17 10501200 3 9 D31 D37 9401050 2 10501200 D21 D27 4 D41 D47 1200 1300 12101310 1 12101310

More information

Comparison of Passive Opening Tests of the Eustachian Tube Takuya Kinoshita, Tadashi Iwano, Eimoto Hamada, Akihiro Kaneko, Yasuo Hosoda, Koichi Ushiro

Comparison of Passive Opening Tests of the Eustachian Tube Takuya Kinoshita, Tadashi Iwano, Eimoto Hamada, Akihiro Kaneko, Yasuo Hosoda, Koichi Ushiro Comparison of Passive Opening Tests of the Eustachian Tube Takuya Kinoshita, Tadashi Iwano, Eimoto Hamada, Akihiro Kaneko, Yasuo Hosoda, Koichi Ushiro and Tadami Kumazawa (Kansai Medical University) Endoscopic

More information

20●12頁●6-14▲放射線科▲.ppt

20●12頁●6-14▲放射線科▲.ppt No.268 Katayama H. et al. Adverse reactions to ionic and nonionic contrast media-a report from the Japanese Committee of the Safety of Contrast Media. Radiology 1990;175:621-628. 12.66% 3.13% 0.22% 0.04%

More information

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1 10O1A 10 10 1 10K1A NASA () SPACE ATLAS 40 1957 1969 10 1986 1990 Freedom 20 000 H2A NASA 1 10K1A 100 10 21 40 1996 ( 200 () 2 10S1A 10 8 57 250 1 10S1A 20 200mmm 2 10S1B 18 18 1 10S1B 40 10 20 2 10S1C

More information

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1-

E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1- E-mail rsakurai@jade.dti.ne.jp 2000. 2. 1-1- LD LD LD -2- MBD Minimal Brain Dysfunction Syndrome -3- Minimal Brain Dysfunction Syndrome : --- WISC-WPPSIK-ABC --- CTMRIEEG --- 40 60-4- -5- MBD MBD MBD MBD

More information

3-2 PET ( : CYRIC ) ( 0 ) (3-1 ) PET PET [min] 11 C 13 N 15 O 18 F 68 Ga [MeV] [mm] [MeV]

3-2 PET ( : CYRIC ) ( 0 ) (3-1 ) PET PET [min] 11 C 13 N 15 O 18 F 68 Ga [MeV] [mm] [MeV] 3 PET 3-1 PET 3-1-1 PET PET 1-1 X CT MRI(Magnetic Resonance Imaging) X CT MRI PET 3-1 PET [1] H1 D2 11 C-doxepin 11 C-raclopride PET H1 D2 3-2 PET 0 0 H1 D2 3-1 PET 3-2 PET ( : CYRIC ) ( 0 ) 3-1-2 (3-1

More information

NEDO

NEDO 10 MRI 1 1 595% 5 IOR 100% MRI MRI MRI MRI MRI MRI 11 MRI 3 2 1 MRI 1 1.5 0.000005 100 5 MRI MRI MRI MRI MRI MRI MRI MRI MRI (1) MRI MRI 0.3 3 MRI 1 / (2) MRI MRI (3)MRI MRI 3 (4)MRI MRI MRI (5)MRI 2006

More information

天草郡市医師会第139回(臨時)代議員会

天草郡市医師会第139回(臨時)代議員会 A 97 2(B A2) 4(A B3) 2 95 B 104 25(A B3) 16(B A2) 9 113 201 27 20 7 208 2 1 13 3 18 4 19 3 3 2 2 13 4 17 3 18 6 26 6 30 17 18 17 17 17 17 18 ( ) 18 ( ) 18 ( ) 18 ( ) 18 ( ) ( ) ( ) ( ) ( ) ( ) 18 ( ) (

More information

1 2 3 4 10 5 30 87 50 20 3 7 2 2 6 3 70 7 5 10 20 20 30 14 5 1,000 24 112 2 3 1 8 110 9 JR 10 110 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 25 30 31 32 25 A 33 B C D E F G PR PR or 34 35

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

Microsoft Word - 01_.doc

Microsoft Word - 01_.doc 287 293 295 296 297 298 299 300301 303 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 ÁÁÁ 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 () 1 (4757

More information

76

76 75 76 77 78 79 80 OM 81,,.,,., 82,,,,,,,,,,, 83,,,,,, 84, CR Card Reader CR CR,,, 85,,, 86,,,,,,,,,,,,,,,,,,,,,, 87 88 89.. 90 91.... 92 93.... 94.. 95 96. 97.. 98 99.. 100 b TDL b b c a c b d 101, a a

More information

untitled

untitled 1 Hitomi s English Tests 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 1 0 1 1 0 1 0 0 0 1 0 0 1 0 2 0 0 1 1 0 0 0 0 0 1 1 1 1 0 3 1 1 0 0 0 0 1 0 1 0 1 0 1 1 4 1 1 0 1 0 1 1 1 1 0 0 0 1 1 5 1 1 0 1 1 1 1 0 0 1 0

More information

1

1 1 2 3 4 5 0% 20% 40% 60% 80% 100% 6 7 8 0% 20% 40% 60% 80% 100% 9 0% 20% 40% 60% 80% 100% 10 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2529 (n=17) 3034 35 (n=21) (n=17) 2529 (n=19) 3034 35 (n=34) (n=64)

More information

Intracranial complications of non-cholesteatomatous otitis media Tetsuya Tono, Akira Ganaha and Tatsuhito Oowa Department of Otolaryngology, Universit

Intracranial complications of non-cholesteatomatous otitis media Tetsuya Tono, Akira Ganaha and Tatsuhito Oowa Department of Otolaryngology, Universit Intracranial complications of non-cholesteatomatous otitis media Tetsuya Tono, Akira Ganaha and Tatsuhito Oowa Department of Otolaryngology, University of the Ryukyus The widespread use of antimicrobial

More information

[FX18]シリーズカタログ

[FX18]シリーズカタログ ICR (db) 6 5 3 2 ICR 1 ICR IEEE spec 2 4 6 8 1 Z (Ohms) 11 15 1 95 Impedance 9.2.4.6.8 1 Time (ns) 213.9 FX18-6 S -.8 SH FX18-6 P -.8 SH FX18-6 P -.8 SV 1 FX18-6 S -.8 SV 15 FX18-6 PS -.8 H 15 Signal

More information

耳展 長 32:6 舩 宏 隆,他 表2 症状 の改 善率 と臨床 病型 表3 レ線 的改 善率 と臨床 病 型 M.N. 14歳 臨 床 症型:浮 腫茸 状 型 手 術 法:両 前篩 骨 洞 開放 術 両 下鼻 道 開 窓術 治療 効 果:両 側著 明改 善 2年 術 前 術 後 症 例1 40 (550) 上 顎 洞 開 窓 術(小 児) 耳展 32:6 M.H. 13歳 臨床 病 型1浮 腫

More information

science

science science IT PERSON TO PERSON EU IT IT WHO TV I T Harvard University Brigham and Women s Hospital, Renal Division UCSF CT MRI IT 1 40 17 3 27 Winslow 1949 Impact Factor 50 1 16 1 NIH Samuel W. Cushman

More information

untitled

untitled Q 40 Q Q A 45 2 2 A 1 60 200 59.95 161 3 3 3 1 Q Q2 Q1 Q Q A2 1 2 Q Q Q Q Q Q A 32 2 U 3 4 Q Q Q Q 10 Q Q Q Q Q Q Q 22 Q Q Q 20 30 Q HP A 34 D K L L 5 Qmm Q 10 Q 21 Q Q Q Q Q Q Q A1 FRP 2 6 Q Q LDK Q Q

More information

untitled

untitled 19 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15 19 19 1 17,676 20.0 2 20,970 24.1 3 4,967 23.2 104,10919 4 8,234 18.0 11,428 22.4 1 0 10,954244 17,107 18.7 136 4.8 12,653205 1,239 13.2 10,056686 27,305514

More information

- 1 -

- 1 - 19 21 - 1 - - 2 - - 3 - - 4 - 19 21 21 2224-5 - 19 2007 21 2009 H18 H27 18 27 10 H18 H22 18 22 22 H19 H21 19 21 21-6 - 20 21 19 2,449,254 2,495,506 1.9% 2,603,427 4.3% 1,593,428 1,582,704 0.7% 1,552,160

More information

2011 2012 4 8 C D! A B

2011 2012 4 8 C D! A B 2011 2012 4 8 C D! A B C D 2013 2014 5/ 6 7 9 11/ 12 1 3 5/6 7 9 11/12 1 3 5 6 7 1971 2003118 9 196338) 7651) 2006 1 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 The Women of Lockerbie 19881221 16243

More information

... 3 CT

... 3 CT CT915 ... 3 CT915... 4... 5... 6... 7... 11... 14... 16... 18... 19... 22... 24... 25... 26... 28... 29... 30... 31 2 3 CT915 120 120 1 1 31 31 4 CT915 s t CR2032 5 1. 2. 5 3. 6 CR2032 CR2032 1. / 1 2.

More information

1

1 1 6 7 8 9 10 11 12 13 14 15 21:00 22:00 23:00 24:00 18:00 19:00 20:00 16 1 3 ). ). ). 6 ). ). 9 10 12 ). ). 15 ). ). ). 20 ). ). ). 26 2 ). 2 39 3 ). 1. 2. 3. 4. 4 5. 6. ). 5 ). ( ) ( TWITraining

More information

橡アロマセラピー症状別処方例.PDF

橡アロマセラピー症状別処方例.PDF 1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

More information

QA Q1. A1. 118 2 Q2. A2. Q3. A3. 1) 2) 3) 4) 5) 6) 7) Q4. A4. 024-536-4343 10:0022:00 03-3264-4343 24 2008/10/15 1 1 2 3 2008/10/15 4: 5() N95 6A() SARS WHO B 7B( 1. 2. (( ) 3. 38 4. 5. 6. 2 2008/10/15

More information

untitled

untitled -3 1 19413-1 -2-3 -4-5 -6-7 -8-9 -10-11( -12-13 -14-15 1 2 3 4 6 7 8 10 11 12 13 14 15 17 18 21 22 23 24 26 27 28 ( 33 40 56 58 2 7 9 14 17 19 30 40 50 60 10 S47 S46 S42 S45 H4 H421 H5 H6 H6 H9 ( S33 S33

More information

1 2 3 4

1 2 3 4 LC-32GH1 LC-32GH2 1 2 3 4 5 4 6 7 8 9 10 11 1 2 3 4444444444 4444444 444444444 OIL BAR BAR CLINIC CLINIC 1 2 1 2 1 2 3 4 1 2 1 2 See page 44 if you wish to display menu screens

More information

喘息について\(公健協会宛02-5作成\)

喘息について\(公健協会宛02-5作成\) Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30

More information

untitled

untitled 2 5 1 5 5.1 5.2 5.3 5.4 5.1 5.3 6 6.1 6.2 2 6.3 F 6.4 2 6.5 6.6 2 2 6.1 6.4 2 6.2 2 6.3 F 6.5 6.6 2 6.1 6.1 1 5 X N 2 /n Z X - / / n Z N 0 1 P -z /2 Z z /2 1- z P Z z = P X-z /2 / n X+ z /2 / n 100 % X-z

More information

41-6_50回中国地方会Pr6N__HP掲載用.indd

41-6_50回中国地方会Pr6N__HP掲載用.indd 2014 9 6 1, 2, 2, 2, 2 1, 2 60.. CT S 5 47 mm, 20 mm. US,,..,,. CT.,,.,. 8.,,.,. 1, 2, 2, 2, 2, 2, 3, 3 1, 2, 3 70 5,, CT. 17, 20, 30..,. Segmental Arterial Mediolysis SAM,.,. SAM,., 50,.,, 70. S 5 SOL.

More information